403 related articles for article (PubMed ID: 26882530)
1. Controlled Release of Dexamethasone From an Intravitreal Delivery System Using Porous Silicon Dioxide.
Hou H; Wang C; Nan K; Freeman WR; Sailor MJ; Cheng L
Invest Ophthalmol Vis Sci; 2016 Feb; 57(2):557-66. PubMed ID: 26882530
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal controlled release of dexamethasone from engineered microparticles of porous silicon dioxide.
Wang C; Hou H; Nan K; Sailor MJ; Freeman WR; Cheng L
Exp Eye Res; 2014 Dec; 129():74-82. PubMed ID: 25446320
[TBL] [Abstract][Full Text] [Related]
3. Tunable sustained intravitreal drug delivery system for daunorubicin using oxidized porous silicon.
Hou H; Nieto A; Ma F; Freeman WR; Sailor MJ; Cheng L
J Control Release; 2014 Mar; 178():46-54. PubMed ID: 24424270
[TBL] [Abstract][Full Text] [Related]
4. New model of proliferative vitreoretinopathy in rabbit for drug delivery and pharmacodynamic studies.
Moon SW; Sun Y; Warther D; Huffman K; Freeman WR; Sailor MJ; Cheng L
Drug Deliv; 2018 Jan; 25(1):600-610. PubMed ID: 29461171
[TBL] [Abstract][Full Text] [Related]
5. Surface engineering of porous silicon microparticles for intravitreal sustained delivery of rapamycin.
Nieto A; Hou H; Moon SW; Sailor MJ; Freeman WR; Cheng L
Invest Ophthalmol Vis Sci; 2015 Jan; 56(2):1070-80. PubMed ID: 25613937
[TBL] [Abstract][Full Text] [Related]
6. A sustained dual drug delivery system for proliferative vitreoretinopathy.
Xiao Y; Choi KS; Warther D; Huffman K; Landeros S; Freeman WR; Sailor MJ; Cheng L
Drug Deliv; 2020 Dec; 27(1):1461-1473. PubMed ID: 33100053
[TBL] [Abstract][Full Text] [Related]
7. Quantitative MR imaging study of intravitreal sustained release of VEGF in rabbits.
Alikacem N; Yoshizawa T; Nelson KD; Wilson CA
Invest Ophthalmol Vis Sci; 2000 May; 41(6):1561-9. PubMed ID: 10798677
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes.
Chang-Lin JE; Burke JA; Peng Q; Lin T; Orilla WC; Ghosn CR; Zhang KM; Kuppermann BD; Robinson MR; Whitcup SM; Welty DF
Invest Ophthalmol Vis Sci; 2011 Jun; 52(7):4605-9. PubMed ID: 21421864
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the release profile and pharmacokinetics of intact and fragmented dexamethasone intravitreal implants in rabbit eyes.
Bhagat R; Zhang J; Farooq S; Li XY
J Ocul Pharmacol Ther; 2014 Dec; 30(10):854-8. PubMed ID: 25411827
[TBL] [Abstract][Full Text] [Related]
10. Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown.
Edelman JL; Lutz D; Castro MR
Exp Eye Res; 2005 Feb; 80(2):249-58. PubMed ID: 15670803
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant.
Chang-Lin JE; Attar M; Acheampong AA; Robinson MR; Whitcup SM; Kuppermann BD; Welty D
Invest Ophthalmol Vis Sci; 2011 Jan; 52(1):80-6. PubMed ID: 20702826
[TBL] [Abstract][Full Text] [Related]
12. Oxidized porous silicon particles covalently grafted with daunorubicin as a sustained intraocular drug delivery system.
Chhablani J; Nieto A; Hou H; Wu EC; Freeman WR; Sailor MJ; Cheng L
Invest Ophthalmol Vis Sci; 2013 Feb; 54(2):1268-79. PubMed ID: 23322571
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic and clinical profile of dexamethasone intravitreal implant.
Robinson MR; Whitcup SM
Expert Rev Clin Pharmacol; 2012 Nov; 5(6):629-47. PubMed ID: 23234323
[TBL] [Abstract][Full Text] [Related]
14. A sustained intravitreal drug delivery system with remote real time monitoring capability.
Hou H; Nieto A; Belghith A; Nan K; Li Y; Freeman WR; Sailor MJ; Cheng L
Acta Biomater; 2015 Sep; 24():309-21. PubMed ID: 26087110
[TBL] [Abstract][Full Text] [Related]
15. A preliminary evaluation of dexamethasone palmitate emulsion: a novel intravitreal sustained delivery of corticosteroid for treatment of macular edema.
Daull P; Paterson CA; Kuppermann BD; Garrigue JS
J Ocul Pharmacol Ther; 2013 Mar; 29(2):258-69. PubMed ID: 23331052
[TBL] [Abstract][Full Text] [Related]
16. Porous silicon based intravitreal platform for dual-drug loading and controlled release towards synergistic therapy.
Warther D; Xiao Y; Li F; Wang Y; Huffman K; Freeman WR; Sailor M; Cheng L
Drug Deliv; 2018 Nov; 25(1):1537-1545. PubMed ID: 29996687
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal sustained-release dexamethasone device in the treatment of experimental uveitis.
Cheng CK; Berger AS; Pearson PA; Ashton P; Jaffe GJ
Invest Ophthalmol Vis Sci; 1995 Feb; 36(2):442-53. PubMed ID: 7843913
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of vitreous clearance and potential retinal toxicity of intravitreal lornoxicam (xefo).
Diakonis VF; Tsourdou A; Tzatzarakis MN; Tsika C; Charisis S; Naoumidi I; Plainis S; Tsilimbaris MK
J Ocul Pharmacol Ther; 2013 Sep; 29(7):627-32. PubMed ID: 23556534
[TBL] [Abstract][Full Text] [Related]
19. The Sustained-Release Dexamethasone Implant: Expanding Indications in Vitreoretinal Disease.
Kapoor KG; Wagner MG; Wagner AL
Semin Ophthalmol; 2015; 30(5-6):475-81. PubMed ID: 24654698
[TBL] [Abstract][Full Text] [Related]
20. Sustained release intravitreal dexamethasone.
Hainsworth DP; Pearson PA; Conklin JD; Ashton P
J Ocul Pharmacol Ther; 1996; 12(1):57-63. PubMed ID: 8925398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
